

OKLAHOMA BOARD OF NURSING  
2915 N. Classen Boulevard, Suite 524  
Oklahoma City, OK 73106  
(405) 962-1800

**CRNA Inclusionary Formulary**

---

**4.0 Antihistamine Drugs**

4:04 First Generation Antihistamines

4:04.04 Diphenhydramine Hydrochloride

4:04.12 Promethazine Hydrochloride

**[CAUTION: BE AWARE OF PEDIATRIC RESTRICTIONS]**

**-12:00 Autonomic Agents**

12:04 Parasympathomimetic (Cholinergic) Agents

Neostigmine Bromide

Physostigmine Salicylate

Pyridostigmine Bromide

12:08 Anticholinergic Agents

Benzotropine Mesylate [NOTE: All drugs reclassified are under 28:36.08; this class will remain as a cross-reference in the 12:00 hierarchy]

12:08.08 Antimuscarinics/antispasmodics

Atropine

Glycopyrrolate

Ipratropium Bromide

Scopolamine

12:12 Sympathomimetic (Adrenergic) Agents

Albuterol

Dobutamine

Ephedrine

Epinephrine

Formoterol

Isoetharine

Isoproterenol

Mephentermine

Metaproterenol

Metaraminol

Midodrine

Norepinephrine

Phenylephrine Bitartrate

Pseudoephedrine

Ritodrine Hydrochloride (not in AHFS)

Salmeterol

Terbutaline Sulfate

12:16 Sympatholytic (Adrenergic Blocking) Agents

Phentolamine

12:20 Skeletal Muscle Relaxants (all intravenous future new drugs approved)

Atracurium Besylate

Pancuronium Bromide

Rocuronium Bromide

Succinylcholine Chloride

Tubocurarine Chloride (not in AHFS)

Vecuronium Bromide

Dantrolene Sodium

Board Approved: 1/20/98

Board Reviewed w/o Revision: 1/28/99; 5/23/06

Board Revised: 9/30/99; 5/25/01; 5/28/02; 5/27/03; 5/25/04; 5/24/05; 5/29/07; 5/27/08

OBN Policy/Guideline - #P50A

Page 1 of 8

H:/SELLis/Executive/Policies/Practice/CRNAIncForm

**16:00 Blood Derivatives**

Albumin Human  
Plasma Protein Fraction

**20:00 Blood Formation and Coagulation**

- 20:12 Antithrombotic Agents  
20:12.04 Anticoagulants  
Enoxaparin  
Heparin
- 20:28 Antihemorrhagic Agents  
20:28.08 Antiheparin Agents  
Protamine Sulfate
- 20:28.16 Hemostatics  
Aminocaproic Acid

**24:00 Cardiovascular Drugs**

- 24:04 Cardiac Drugs  
Amiodarone  
Disopyramide  
Digoxin  
Dofetilide  
Encainide  
Flecainide  
Ibutilide  
Lidocaine  
Procainamide  
Propafenone  
Quinidine
- 24:08 Hypotensive Agents  
Clonidine  
Hydralazine  
Methyldopa  
Sodium Nitroprusside
- 24:12 Vasodilating Agents  
Nicardipine  
Nifedipine  
Nitroglycerine
- 24:24  $\beta$  Adrenergic Blocking Agents  
Atenolol  
Esmolol Hydrochloride  
Metoprolol  
Nadolol  
Propranolol  
Timolol  
Labetalol
- 24:28 Calcium-Channel Blocking Agents  
Verapamil
- 24:32 Renin-Angiotensin-Aldosterone System Inhibitors  
Captopril

Board Approved: 1/20/98

Board Reviewed w/o Revision: 1/28/99; 5/23/06

Board Revised: 9/30/99; 5/25/01; 5/28/02; 5/27/03; 5/25/04; 5/24/05; 5/29/07; 5/27/08

OBN Policy/Guideline - #P50A

Page 2 of 8

H:/SELLis/Executive/Policies/Practice/CRNAIncForm

**28:00 Central Nervous System Agents**

- 28:04 General Anesthetics (all in this class approved including future new drugs)
  - Propofol
  - Methohexital
- 28:08 Analgesics and Antipyretics
  - Aspirin
  - Ibuprofen
  - Indomethacin
  - Ketorolac
  - Celecoxib
- 28:08.08 Opiate Agonists (future new drugs approved)
  - Codeine
  - Fentanyl
  - Hydrocodone
  - Hydromorphone
  - Levorphanol
  - Meperidine
  - Morphine
  - Remifentanyl (not in AHFS)
  - Sufentanil Citrate
  - Tramadol
- 28:08.12 Opiate Partial Agonists (all in this class approved including future new drugs)
  - Buprenorphine
  - Butorphanol
  - Nalbuphine
  - Pentazocine
- 28:08.92 Analgesics and Antipyretic, Miscellaneous
  - Acetaminophen
  - Salicylamide
  - Sodium Thiosalicylate
- 28:10 Opiate Antagonists (all in this class approved including future new drugs)
  - Nalmefene
  - Naloxone
  - Naltrexone
- 28:12 Anticonvulsants
  - 28:12.04 Barbituates
    - Phenobarbital
  - 28:12.08 Benzodiazepines
    - Clonazepam
  - 28:12.12 Hydantoins
    - Ethoin
    - Fosphenytoin
    - Phenytoin
  - 28:12.92 Anticonvulsants, Miscellaneous
    - Carbamazepine
    - Felbamate
    - Gabapentin
    - Lamotrigine
    - Magnesium Sulfate
    - Valproate/Divalproex
- 28:16 Psychotherapeutic Agents
  - Prochlorperazine
  - Haloperidol

Board Approved: 1/20/98

Board Reviewed w/o Revision: 1/28/99; 5/23/06

Board Revised: 9/30/99; 5/25/01; 5/28/02; 5/27/03; 5/25/04; 5/24/05; 5/29/07; 5/27/08

OBN Policy/Guideline - #P50A

Page 3 of 8

H:/SELLIS/Executive/Policies/Practice/CRNAIncForm

- 28:20 Anorexigenic Agents and Respiratory and Cerebral Stimulants
  - Caffeine/caffeine and Sodium Benzoate
  - Doxapram
- 28:24 Anxiolytics, Sedatives, and Hypnotics
  - 28:24.04 Barbiturates (future new drugs approved)
    - Phenobarbital
  - 28:24.08 Benzodiazepines (future new drugs approved)
    - Chlordiazepoxide
    - Diazepam
    - Lorazepam
    - Midazolam
  - 28:24.92 Anxiolytics, Sedatives and Hypnotics; Miscellaneous
    - Chloral Hydrate
    - Droperidol: [NOTE: Adult dosage not to exceed a total dose of 1.25 mg; Pediatric dosage not to exceed a one-time dose of 10 mcg/kg.]
    - Hydroxyzine
    - Promethazine
    - Dexmedetomidine
- 28:36 Antiparkinsonian Agents
  - 28:36.08 Anticholinergic Agents
    - Benzotropine Mesylate
- 28:92 Central Nervous System Agents, Miscellaneous
  - Flumazenil

**36:00 Diagnostic Agents**

- 36:40 Kidney Function\*
  - Indigo Carmine (Indigotindisulfonate)
- 36:56 Myasthenia Gravis\*
  - Edrophonium Chloride

**40:00 Electrolytic, Caloric, and Water Balance**

- 40:08 Alkalinizing Agents
  - Sodium Bicarbonate
  - Citrate Salts
  - Sodium Lactate
  - Tromethamine
- 40:12 Replacement Preparations
  - Pentastarch (not in AHFS)
  - Calcium Salts
  - Dextran 40
  - Dextran 70
  - Dextran 75 (not in AHFS) **[CAUTION: POTENTIAL COMPLICATION OF ANAPHYLACTIC REACTION TO DEXTRAN 75]**
  - Electrolyte Solutions\*
  - Hetastarch
  - Potassium Supplements
  - Sodium Chloride
- 40:20 Caloric Agents
  - Dextrose
  - Invert Sugar
- 40:24 Salt and Sugar Substitutes (not in AHFS)

Board Approved: 1/20/98

OBN Policy/Guideline - #P50A

Board Reviewed w/o Revision: 1/28/99; 5/23/06

Page 4 of 8

Board Revised: 9/30/99; 5/25/01; 5/28/02; 5/27/03; 5/25/04; 5/24/05; 5/29/07; 5/27/08

H:/SELLis/Executive/Policies/Practice/CRNAIncForm

- 40:28 Diuretics  
 Chlorothiazide  
 Bumetanide  
 Furosemide  
 Mannitol
- 40:36 Irrigating Solutions \*  
 Sterile water for injection\*

**48:00 Respiratory Tract Agents** (all in this class approved including future new drugs)

- 48:08 Antitussives  
 Benzonatate  
 Codeine  
 Dextromethorphan  
 Hydrocodone
- 48:16 Expectorants  
 Guaifenesin  
 Potassium Iodide
- 48:24 Mucolytic Agents  
 Acetylcysteine (also see 92:00)

**52:00 Eye, Ear, Nose, and Throat (EENT) Preparations**

- 52:16 Local Anesthetics  
 Benzocaine  
 Dyclonine  
 Proparacaine  
 Tetracaine
- 52:32 Vasoconstrictors  
 Epinephrine  
 Naphazoline  
 Oxymetazoline  
 Phenylephrine  
 Propylhexedrine  
 Tetrahydrozoline
- 52:40 Antiglaucoma Agents  
 52:40.12 Carbonic Anhydrase Inhibitors  
 Acetazolamide

**56:00 Gastrointestinal Drugs**

- 56:04 Antacids and Adsorbents  
 Aluminum Carbonate  
 Aluminum Hydroxide  
 Aluminum Phosphate  
 Antacids  
 Calcium Carbonate  
 Charcoal, Activated  
 Dihydroxyaluminum Aminoacetate  
 Dihydroxyaluminum Sodium Carbonate  
 Magaldrate  
 Magnesium Carbonate  
 Magnesium Hydroxide  
 Magnesium Oxide  
 Magnesium Trisilicate  
 Sodium Bicarbonate

Board Approved: 1/20/98

Board Reviewed w/o Revision: 1/28/99; 5/23/06

Board Revised: 9/30/99; 5/25/01; 5/28/02; 5/27/03; 5/25/04; 5/24/05; 5/29/07; 5/27/08

OBN Policy/Guideline - #P50A

Page 5 of 8

H:/SELLis/Executive/Policies/Practice/CRNAIncForm

- 56:22 Antiemetics
  - 56:22.08 Antihistamines
    - Dimenhydrinate
    - Meclizine
    - Prochlorperazine
    - Trimethobenzamide
  - 56:22.20 5-HT<sub>3</sub> Receptor Antagonists
    - Dolasetron
    - Granisetron
    - Ondansetron
- 56:28 Antiulcer Agents and Acid Suppressants
  - 56:28.12 Histamine H<sub>2</sub>-Antagonists
    - Cimetidine
    - Famotidine
    - Nizatidine
    - Ranitidine
- 56:32 Prokinetic Agents
  - Metoclopramide

**68:00 Hormones and Synthetic Substitutes**

- 68:04 Adrenals (all in this class approved including future new drugs)
  - Beclomethasone
  - Betamethasone
  - Cortisone Acetate
  - Dexamethasone
  - Fludrocortisone
  - Flunisolide
  - Hydrocortisone
  - Methylprednisolone
  - Prednisolone
  - Prednisone
  - Triamcinolone
- 68:20 Antidiabetic Agents
  - 68:20.08 Insulins
    - Insulin Aspart
    - Insulin Glargine
    - Insulin Human
    - Insulin, Isophane
    - Insulin Lispro
    - Insulin Zinc
  - 68:20.20 Sulfonylureas
    - Chlorpropamide
    - Glimepiride
    - Glipizide
    - Glyburide
    - Tolazamide
    - Tolbutamide
- 68:22 Antihypoglycemic Agents
  - 68:22.12 Glycogenolytic Agents
    - Glucagon

68:28 Pituitary  
Corticotropin  
Desmopressin  
Vasopressin

**72:00 Local Anesthetics** (all in this class approved including future new drugs)

Articaine  
Bupivacaine  
Chloroprocaine  
Etidocaine (not in AHFS)  
Lidocaine  
Mepivacaine  
Prilocaine  
Procaine  
Ropivacaine (not in AHFS)  
Tetracaine

**76:00 Oxytocics**

Dinoprostone  
Ergonovine/Methergonovine  
Oxytocin  
Sodium Chloride 20% Injection  
Urea 40-50% Injection  
Hemabate

**84:00 Skin and Mucous Membrane Agents**

84:08 Antipruritics and Local Anesthetics (all in this class approved including future new drugs)

Benzocaine  
Dibucaine  
Doxepin  
Dyclonine (see 52:16 – Local Anesthetics for EENT Preparations)  
Ethyl Chloride  
Phenazopyridine  
Pramoxine  
EMLA (not in AHFS)

**86:00 Smooth Muscle Relaxants**

86:16 Respiratory Smooth Muscle Relaxants

Aminophylline  
Theophyllines

**92:00 Miscellaneous Therapeutic Agents**

Antidotes

Acetylcysteine  
Methylene Blue\*  
Ascorbic Acid\* (Vitamin C) [listed under 88:12]

Other Miscellaneous Therapeutic Agents

Adenosine Phosphate\*

**Regulatory Authority:**

59 O.S. §567.4b. C.

**Reference:**

American Hospital Formulary Service®. *AHFS Drug Information 2008*®. Published by Authority of the Board of the American Society of Health-System Pharmacists®, Bethesda, MD.

\* Omitted from the print version of *AHFS Drug Information* because of space limitations, as stated by the publisher.

Board Approved: 1/20/98

Board Reviewed w/o Revision: 1/28/99; 5/23/06

Board Revised: 9/30/99; 5/25/01; 5/28/02; 5/27/03; 5/25/04; 5/24/05; 5/29/07; 5/27/08

OBN Policy/Guideline - #P50A

Page 8 of 8

H:/SEllis/Executive/Policies/Practice/CRNAINcForm